Business Description
Xvivo Perfusion AB
ISIN : SE0004840718
Total Employee Number:
199Compare
Compare
Traded in other countries / regions
XVIVO.Sweden0RKL.UKXVIPF.USA3XV.Germany IPO Date
2014-02-05Description
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.51 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 1.31 | |||||
Interest Coverage | 6.91 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 18.62 | |||||
Beneish M-Score | -2.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.3 | |||||
3-Year EBITDA Growth Rate | 17.3 | |||||
3-Year EPS without NRI Growth Rate | 8.8 | |||||
3-Year FCF Growth Rate | -11.3 | |||||
3-Year Book Growth Rate | 11.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 126.66 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 26.95 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.59 | |||||
9-Day RSI | 69.7 | |||||
14-Day RSI | 82.58 | |||||
3-1 Month Momentum % | 28.84 | |||||
6-1 Month Momentum % | 41.98 | |||||
12-1 Month Momentum % | -2.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.52 | |||||
Quick Ratio | 3.1 | |||||
Cash Ratio | 1.92 | |||||
Days Inventory | 408.46 | |||||
Days Sales Outstanding | 70.84 | |||||
Days Payable | 57.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | -1.04 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.11 | |||||
Operating Margin % | 11.23 | |||||
Net Margin % | 8.85 | |||||
EBITDA Margin % | 11.23 | |||||
FCF Margin % | 21.88 | |||||
OCF Margin % | 21.88 | |||||
ROE % | 3.5 | |||||
ROA % | 3.1 | |||||
ROIC % | 3.51 | |||||
3-Year ROIIC % | 9.46 | |||||
ROC (Joel Greenblatt) % | 19.47 | |||||
ROCE % | 4.19 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 119.15 | |||||
Forward PE Ratio | 77.34 | |||||
PE Ratio without NRI | 119.15 | |||||
Shiller PE Ratio | 261.09 | |||||
PS Ratio | 10.59 | |||||
PB Ratio | 4.07 | |||||
Price-to-Tangible-Book | 13.24 | |||||
Price-to-Free-Cash-Flow | 48.63 | |||||
Price-to-Operating-Cash-Flow | 48.63 | |||||
EV-to-EBIT | 92.1 | |||||
EV-to-Forward-EBIT | 56.59 | |||||
EV-to-EBITDA | 92.1 | |||||
EV-to-Forward-EBITDA | 35.72 | |||||
EV-to-Revenue | 10.35 | |||||
EV-to-Forward-Revenue | 8.14 | |||||
EV-to-FCF | 47.53 | |||||
Price-to-GF-Value | 0.7 | |||||
Price-to-Projected-FCF | 3.52 | |||||
Price-to-Median-PS-Value | 0.57 | |||||
Price-to-Graham-Number | 8.36 | |||||
| Price-to-Net-Current-Asset-Value | 20.72 | |||||
| Price-to-Net-Cash | 966.7 | |||||
Earnings Yield (Greenblatt) % | 1.09 | |||||
FCF Yield % | 2.06 | |||||
Forward Rate of Return (Yacktman) % | 11.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:XVIPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xvivo Perfusion AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 89.048 | ||
| EPS (TTM) ($) | 0.252 | ||
| Beta | 0.9247 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.41 | ||
| Volatility % | 60.92 | ||
| 14-Day RSI | 82.58 | ||
| 14-Day ATR ($) | 0.064444 | ||
| 20-Day SMA ($) | 29.11777 | ||
| 12-1 Month Momentum % | -2.36 | ||
| 52-Week Range ($) | 16.975 - 30.95 | ||
| Shares Outstanding (Mil) | 31.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xvivo Perfusion AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xvivo Perfusion AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-23 14:00 | In 109 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 07:30 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-14 14:00 | In 8 days | ||
| Second quarter earnings results for 2026 | 2026-07-14 07:30 | In 8 days | ||
| General meeting for 2025 | 2026-04-27 14:00 | 22.81 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-24 14:00 | 22.81 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-24 07:30 | 22.81 (+0.00%) | ||
| Annual report for 2025 | 2026-04-01 | 22.81 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-01-27 14:00 | 23.25 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-01-27 07:30 | 23.25 (+0.00%) |
Show
Entries
Xvivo Perfusion AB Frequently Asked Questions
What is Xvivo Perfusion AB(XVIPF)'s stock price today?
The current price of XVIPF is $29.00. The 52 week high of XVIPF is $30.95 and 52 week low is $16.98.
When is next earnings date of Xvivo Perfusion AB(XVIPF)?
The next earnings date of Xvivo Perfusion AB(XVIPF) is 2026-07-14.
Does Xvivo Perfusion AB(XVIPF) pay dividends? If so, how much?
Xvivo Perfusion AB(XVIPF) does not pay dividend.
Guru Commentaries on OTCPK:XVIPF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Interim Report January-September 2024 | 2024-10-24 | ||
| Conference Call on Interim Report | 2024-10-10 | ||
| XVIVO to Acquire a Unique Communication Platform for the Transplant Process | 2024-09-19 | ||
| Nomination Committee of XVIVO Perfusion AB (publ) | 2024-09-06 | ||
| Results From European Randomized Controlled Study Using XVIVO's Heart Technology Published in The Lancet | 2024-08-16 | ||
| Interim Report January - June 2024 | 2024-07-12 | ||
| Interim Report January - June 2024 | 2024-07-12 | ||
| Conference call on Interim Report | 2024-06-25 | ||
| Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ) | 2024-04-25 | ||
| Interim report January-March 2024 | 2024-04-24 |
Articles on Xvivo Perfusion AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers